Illumina, Inc. (ILMN) Bundle
An Overview of Illumina, Inc. (ILMN)
General Summary of Illumina, Inc. (ILMN)
Illumina, Inc. is a biotechnology company headquartered in San Diego, California, founded in 1998. The company specializes in DNA sequencing and array-based technologies.
Key Products and Services:
- Next-Generation Sequencing (NGS) platforms
- NovaSeq X Series sequencing systems
- Clinical genomic testing solutions
- Genomic research technologies
Company Sales Performance in 2023:
| Metric | Value |
|---|---|
| Total Revenue | $4.25 billion |
| Product Revenue | $3.68 billion |
| Service Revenue | $570 million |
Financial Performance
Financial Highlights for Fiscal Year 2023:
| Financial Metric | Amount |
|---|---|
| Gross Margin | 68.4% |
| Operating Expenses | $2.1 billion |
| Net Income | $436 million |
Industry Leadership
Market Position Indicators:
- Global market share in DNA sequencing: 75%
- Number of installed sequencing systems worldwide: 27,000+
- Genomic research platforms in use: 90% of global genomic research
Illumina continues to dominate the genomic sequencing technology market with cutting-edge innovations and comprehensive scientific solutions.
Mission Statement of Illumina, Inc. (ILMN)
Mission Statement of Illumina, Inc. (ILMN)
Illumina's mission statement focuses on unlocking the power of the genome to improve human health.
Core Components of Mission Statement
| Component | Specific Details | 2024 Metrics |
|---|---|---|
| Genomic Innovation | Advanced sequencing technologies | $4.7 billion R&D investment |
| Healthcare Transformation | Precision medicine solutions | Over 7,500 clinical trials supported |
| Global Impact | Worldwide genomic research | Operations in 55+ countries |
Strategic Focus Areas
- Genomic sequencing accuracy: 99.999%
- Cost per human genome sequencing: $200
- Annual genomic data generation: 5 petabytes
Technology Capabilities
Illumina's genomic sequencing platforms process approximately 90% of global sequencing data, with NovaSeq X Series generating 16 terabytes of data per run.
Market Position
| Metric | 2024 Value |
|---|---|
| Market Share | 78% genomic sequencing market |
| Annual Revenue | $4.3 billion |
| Research Collaborations | 320+ active partnerships |
Vision Statement of Illumina, Inc. (ILMN)
Vision Statement of Illumina, Inc. (ILMN) in 2024
Genomic Transformation ObjectiveIllumina's vision focuses on unlocking the power of the genome to improve human health. As of 2024, the company aims to reduce genome sequencing costs to $200 per human genome.
| Vision Metric | 2024 Target |
|---|---|
| Genome Sequencing Cost | $200 per human genome |
| Annual Genomic Data Generation | Over 7 petabytes |
Illumina targets accelerating genomic research and precision medicine applications across multiple sectors.
- Healthcare diagnostics
- Oncology screening
- Rare disease identification
- Agricultural genomics
| Geographic Expansion | 2024 Reach |
|---|---|
| Countries with Illumina Technology | Over 130 countries |
| Research Institutions Served | More than 7,500 globally |
Illumina continues investing in next-generation sequencing platforms with advanced capabilities.
- NovaSeq X Series deployment
- AI-enhanced genomic analysis
- Enhanced machine learning algorithms
Core Values of Illumina, Inc. (ILMN)
Core Values of Illumina, Inc. (ILMN) in 2024
Innovation and Scientific Excellence
Illumina invested $848.4 million in research and development in 2023. The company holds 6,013 issued patents as of December 2023.
| R&D Metric | 2023 Value |
|---|---|
| R&D Expenditure | $848.4 million |
| Total Issued Patents | 6,013 |
Customer-Centric Approach
Illumina serves over 25,000 active customers globally across research, clinical, and applied markets.
- Customer segments include academic institutions
- Pharmaceutical companies
- Biotechnology firms
- Genomic research centers
Ethical and Responsible Innovation
Illumina's total revenue in 2023 was $4.25 billion, with a commitment to responsible genomic technologies.
| Ethical Innovation Metric | 2023 Value |
|---|---|
| Total Company Revenue | $4.25 billion |
| Genomic Testing Platforms | 17 active platforms |
Collaborative Ecosystem
Illumina maintains partnerships with 500+ global organizations across healthcare and research domains.
- Academic research collaborations
- Pharmaceutical research partnerships
- Clinical diagnostic networks
Sustainability and Social Responsibility
Illumina reduced carbon emissions by 22% in 2023 compared to 2022 baseline.
| Sustainability Metric | 2023 Value |
|---|---|
| Carbon Emission Reduction | 22% |
| Renewable Energy Usage | 35% of total energy consumption |
Illumina, Inc. (ILMN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.